SELLAS Life Sciences Group, Inc.

SLS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2010
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $7.9M
SG&A Expense $8.8M
Operating Income $-12.0M
Operating Margin
Interest Expense
Pretax Income $-12.0M
Income Tax Expense
Net Income $-12.0M
Net Margin
EPS (Basic) $-0.34
EPS (Diluted) $-0.34
Shares Outstanding (Basic) 36.7M
Shares Outstanding (Diluted) 36.7M
Dividends Per Share
← Newer Page 3 of 3 Older →